

A Randomized Study Using Three Vitamin D3 Formulations to Assess 25-Hydroxy Vitamin D and Calcium Levels after 8-Week Treatment Period

Rajendra G. Sonde^{1*}, Ashish Mungantiwar², Sunil Jaiswal³, Sanjay Pawar⁴, Shrikant Chakkarwar⁵

¹Jaoli Society Limited, Mumbai, India

²Executive President, Department of Medical Services, Macleods Pharmaceuticals Limited, Mumbai, India

³Vice President, Department of Product Development and Research, Macleods Pharmaceuticals Limited, Mumbai, India

⁴General Manager, Department of Product Development and Research, Macleods Pharmaceuticals Limited, Mumbai, India

⁵Sr. Group Leader, Department of Product Development and Research, Macleods Pharmaceuticals Limited, Mumbai, India

Abstract: Background: Vitamin D has a vital role in bone metabolism and promotes the absorption of calcium in the intestine. Thus, adequate level of vitamin D is of critical importance. **Methods:** A prospective, randomized, comparative, open-label, parallel-group study evaluated the efficacy, safety and tolerability of three Vitamin D3 products in patients with vitamin D3 deficiency or insufficiency. These products included soft gelatin capsule, granules, and chewable tablet. The dosing regimen was once a week for eight weeks. Change in levels of 25-hydroxyvitamin D and calcium were analyzed. **Results:** The change in 25-hydroxyvitamin D levels from baseline to week 8, and the results of paired t-test indicated statistically significant rise in 25-hydroxyvitamin D levels in each group. The mean percentage improvement in 25-hydroxyvitamin D was in the order: chewable tablet>capsule>granules. The chewable tablet showed an additional important benefit of highest rise in calcium levels, and the rise was in the order: chewable tablet>capsule>granules. Furthermore, no adverse event was noted in any group. **Conclusion:** The efficacy of the chewable tablet in improving both 25-hydroxyvitamin D and calcium levels along with the cost-effectiveness, ease of use, and palatability makes it an attractive choice over other oral formulations in treatment of patients with 25-hydroxyvitamin D insufficiency or deficiency.

Keywords: Calcium, efficacy, supplementation, vitamin d3, 25-hydroxyvitamin D.

1. Introduction

Vitamin D, a group of sec steroids comprising vitamin D2 (ergocalciferol) and D3 (cholecalciferol), has a vital role in Phosphorous and calcium metabolism and maintenance of healthy immune system [1, 2, 3]. Exposing the skin to

ultraviolet B rays leads to vitamin D3 production from 7-dehydrocholesterol; the dietary sources provide both vitamin D2 and D3. In the liver, vitamin D2 and D3 are converted to a prohormone calcidiol (25-hydroxyvitamin D). The measurement of 25-hydroxyvitamin D is the best method to diagnose the vitamin D status of a person [2, 4]. Vitamin D and its metabolites also have numerous clinical applications, including its effectiveness in rickets, hyperparathyroidism, pseudo hypothyroidism, renal osteodystrophy, osteoporosis(steroid-induced, postmenopausal, senile), anticonvulsant drug-induced osteomalacia, hepatic disorders, depression, cancer, obesity, heart disease, Parkinson's disease, influenza, bacterial vaginitis, and many others [5-8]. Vitamin D is primarily involved in promoting the absorption of calcium from the intestine by inducing the formation of calcium binding proteins causing demineralization of bones [1, 9]. Calcium is essential to maintain strong bones and perform vital functions, including supporting the structure and hardness of teeth and bones, movement of muscles, and transfer of messages between the brain and the body via nerves. It also supports the supply of blood to the body and release of hormones and enzymes affecting every function in the human body [10]. Although calcium is an abundantly found mineral in variety of foods, its absorption in the body requires vitamin D and deficiency of vitamin D may impact health causing muscle weakness, skeletal fragility, and several non-skeletal diseases [1, 9, and 10]. Thus, vitamin D supplementation is a recommended safe and effective method for those who do not get enough exposure to

*Corresponding author: drashish@macleodpharma.com

the sun or are vitamin D deficient [11, 12].

As the production of vitamin D in the skin is influenced by factors, such as clothing, time of the day, latitude, altitude, age, pigmentation, and use of sunscreen, deficiency is highly prevalent worldwide, including India. It is also because of the limited dietary sources of vitamin D, and fortification is optional but inconsistent, insufficient, or nonexistent, causing a large population to rely on production of vitamin D in the skin [2, 11, and 13]. Thus, we can consider supplementation as an effective method. Supplementation of vitamin D3 can be through various oral products; however, the absorption varies based on the dosage form used. In addition, nanotechnology is an effective way to improve the absorption, and thus, improves the bioavailability of oral vitamin D3 [4]. Thus, we included a product made with nanotechnology, the chewable tablet, in our study. Although several oral dosage forms of vitamin D3 are available in the market, there is no published literature comparing the effectiveness and safety of granules, chewable tablets, and capsules in a single study [4]. Therefore, we aimed to evaluate and compare the efficacy, safety, and tolerability of different vitamin D3 products, including granules, chewable tablets, and capsules, in adults with 25-hydroxyvitamin D deficiency or insufficiency.

2. Methods

This prospective, randomized, comparative, open-label, parallel-group study evaluated the efficacy, safety and tolerability of three Vitamin D3 products. Ethics Committee approval was obtained prior to initiating the study and good clinical practice guidelines as applicable was followed during the entire study period.

1) Screening and eligibility criteria

All the patients aged ≥ 18 years who were – not participating in any other clinical trial during the study. Patients with – calcium level < 8 mg/dL or > 10.5 mg/dL at baseline; 25-hydroxyvitamin D < 10 ng/mL or > 30 ng/mL at baseline; hypersensitivity to the study treatment a history of chronic disease; current significant acute or chronic illness; pregnancy and lactation; no tolerability to oral medications; use of glucocorticosteroids, anticonvulsants, anti-tubercular, diuretic, and cholesterol-lowering drug therapy in previous three months; prior diagnosis of cancer and current treatment with radiation, chemotherapy, or immunotherapy; a risk of being exposed to sun during the study; a recent tour to the beach or experienced sun bath; dependency on drug or alcohol within one year prior to screening; or circumstance that could compromise the integrity of the study data or affect the analyses if the disease exacerbates during the study or place the subject at risk by participating in the study, in the opinion of the investigator, were excluded from participating in this study.

2) Randomization

Randomization was performed by using block randomization technique by generating a list of numbers in a statistical program. Patients were randomized in equal ratio to the three treatment groups to include approximately 15 patients in each group.

3) Treatment groups and dosing regimen

The three treatments in the study included vitamin D3 60K international units (IU) and were:

- Treatment A: Uprise D3 soft gelatin capsule (of Alkem Laboratories)
- Treatment B: Calcirol granules (of Cadila Pharmaceuticals)
- Treatment C: Gen D3 Nano chewable tablet (of Macleods Pharmaceuticals).

4) Statistical analysis

Statistical analysis was performed on intent to treat (ITT) population using Statistical Analysis System® (SAS®), (SAS Institute Inc., Cary, USA) Version 9.4 or higher. ITT population included all randomized patients who were enrolled in the study and received at least one dose of the allocated study treatment. Statistical test was performed at 5% level of significance. Analyses were done by 2-sided 5% level of significance for both primary and secondary endpoint. ANOVA was used for between treatment group comparisons and paired 't' test was used for within treatment group comparison of parameters.

5) Primary efficacy analysis

The mean change in 25-hydroxyvitamin D from baseline (day 1 of week 1) to endpoint, i.e., week 8 (post-dose) was analyzed.

6) Secondary efficacy analysis

The mean change in serum calcium from baseline (day 1 of week 1) to week 8 (post-dose) was analyzed.

3. Results

This study included adult men and women with normal mean BMI of 25.03 kg/m². The mean age of the patients included in this study was 33.98 years.

1) Patient disposition

One patient receiving chewable tablet and one patient receiving granules were withdrawn from the study on their own accord after 3rd and 5th dose, respectively. Among those who completed the study, one patient receiving granules did not report to the facility for dosing of week 3.

2) Rising Trend in 25-hydroxyvitamin D levels

The mean 25-hydroxyvitamin D levels indicated a rise in all the treatment groups at each week during the 8 week treatment period, except at week 5. As per the laboratory range for vitamin D, < 10 ng/mL indicates deficiency, 10 to 30 ng/mL indicates insufficiency, 30 to 100 ng/mL indicates sufficiency and > 100 ng/mL indicates hypervitaminosis D. The baseline and week 8 values of mean 25-hydroxyvitamin D in our study are demonstrated in Table 1. At week 3, all the products except granule demonstrated a vitamin D level > 30 ng/mL, i.e., sufficiency range. Patients in all the treatment groups achieved sufficiency band of vitamin D at week 8. Although the numerical values suggest that capsule had a higher value than chewable tablet, the percentage rise was significantly higher in Chewable tablet. (Table 1 and Figure 1).

3) Primary efficacy endpoint

The mean percentage change in 25-hydroxyvitamin D levels from baseline (day 1 of week 1) to week 8 (post-dose), and the results of within treatment comparison by paired t-test in each treatment group indicated statistically significant change in 25-hydroxyvitamin D levels in each treatment group. The

highest rise in calcium levels after vitamin D3 supplementation.

Chian CM *et al.*, 2016, conducted a systematic review of six published papers to identify the effects of vitamin D supplementation on muscle strength in athletes. Vitamin D3 was administered in four studies and vitamin D2 was administered in the other two studies. The duration of the study and dose were from 6 weeks to 4 months and 400 to 8,500 IU

Table 1
Mean percentage change in 25-hydroxyvitamin D levels form baseline to week 8

Vitamin D ₃ 60K IU Products	N	Mean 25-hydroxyvitamin D levels (ng/mL)		Mean Differences (ng/mL)	% Change	P-Value
		Baseline	Week 8			
Chewable tablet	13	14.54	57.62	43.08±11.60	296.30	0.000000014134
Soft gelatin capsule	14	16.47	62.21	45.74±18.10	277.71	0.000000342682
Granules	11	14.2	40.68	26.48± 10.34	186.49	0.000006933862

P-value<0.05: Statistically significant; IU: International units; N: Number of patients analyzed; SD: Standard deviation

Table 2
Mean percentage change in serum calcium levels from baseline to week 8

Vitamin D ₃ 60K IU Products	N	Mean serum calcium levels (mg/dL)		Mean Difference*±SD (mg/dL)	% Change	P-Value
		Baseline	Week 8			
Chewable tablet	13	8.92	9.43	0.51±0.58	5.77	0.007451*
Soft gelatin capsule	14	8.86	9.17	0.30±0.53	3.43	0.053356
Granules	11	9.1	9.19	0.09±0.36	1.02	0.411832

P-value<0.05: Statistically significant i.e. Endpoint changes from baseline. IU: International units; N: Number of subjects analyzed; statistically significant

percentage change in 25-hydroxyvitamin D levels at week 8 was found to be in the order: chewable tablet>capsule>granules. Chewable tablet was found to have a significantly higher probability of changes in 25-hydroxyvitamin D levels from baseline to week 8 than capsule and granule formulations. (Table 1 and Figure 1).

4) Secondary efficacy endpoint

The mean serum calcium level in each treatment group was assessed at baseline and at each week during the 8-week treatment period (Figure 2). Although rise in calcium level was observed with all the treatments used in our study, only chewable tablet demonstrated statistically significant rise in calcium levels (Table 2, Figure 2, and Figure 3).

5) Safety endpoint

No adverse events were reported in any of the treatment groups throughout the study period, and all the products used were safe and tolerable.

4. Discussion

All the vitamin D3 products used in our study showed significant rise in levels of 25-hydroxyvitamin D. Chewable tablet has high probability of changes from baseline to week 8 than capsule and granule formulations. In our study, capsule (62.21 ng/mL), chewable tablet (57.62 ng/mL), and granules (40.68 ng/mL) showed improvements within the safe range that will not lead to vitamin D toxicity or hypervitaminosis D, a condition characterized by hypercalcemia, hypercalciuria, and elevated vitamin D>150 ng/ml. The mean percentage improvement in 25-hydroxyvitamin D was in the order: chewable tablet>capsule>granules. The rise in calcium level was in the order: chewable tablet>capsule>granules. Vitamin D is primarily involved in promoting the absorption of calcium from the intestine by inducing the formation of calcium binding proteins causing remineralization of bones [1, 9]. This was demonstrated in our study, wherein chewable tablet showed

per day, respectively. The results indicated that vitamin D2 may be ineffective in improving muscle strength. However, vitamin D3 supplementation may improve muscle function parameters. Vitamin D3 supplementation led to improvements in muscle strength or significant improvements in the outcome measure [14]. Thus, it supports the use of vitamin D3 as a relatively more effective supplementation for vitamin D than vitamin D2. Reid IR *et al.*, 2013, published a systematic review and meta-analysis, including all randomized trial available at the time of publication, reporting the effectiveness of vitamin D supplementation on bone mineral density. The meta-analysis demonstrated that there could be small benefit at femoral neck through vitamin D supplementation [15].




Fig. 1. Mean percentage change in 25-hydroxyvitamin D levels form baseline to week 8

Another meta-analysis of randomized controlled trial estimated the effects of vitamin D3 supplementation in prevention of hip and non-vertebral fractures. A daily dose of 700 to 800 IU lowered the relative risk of hip fracture and non-vertebral fracture by 26% and 23%, respectively. However, a daily oral dose of 400 IU is inadequate to prevent fractures [16]. Thus, the published literatures demonstrate the role of vitamin D3 supplementation in improving muscle strength and reducing the risk of fractures which is possibly related to the rise in

calcium levels as vitamin D is involved in calcium metabolism. Our study is in line with the available literatures indicating the efficacy and safety of different formulations of vitamin D3 and varying levels of 25-hydroxy vitamin D achieved in each group at the end of study.




Fig. 2. Mean serum calcium levels (mg/dL) in each treatment group (vitamin D₃ 60K IU) during the study period.




Fig. 3. Mean percentage change in calcium levels from baseline to week 8

5. Conclusion

Vitamin D3 supplementation is an effective way to prevent and manage several health conditions as well as to maintain healthy bones. The maximum percentage rise in 25-hydroxy vitamin D level was noted with chewable tablet followed by capsule and granules, respectively. Statistically significant rise in calcium level was noted only with chewable tablet. The chewable table is formulated using nanotechnology, indicating the role of nanotechnology in increasing the 25-hydroxyvitamin D and calcium absorption from the formulation. Chewable tablet, along with rise in vitamin D3, showed additional important benefit of highest rise in calcium levels; the cost-effectiveness, palatability, and patient-friendliness of chewable tablet over other formulations in the study may be considered as advantageous factors for patient compliance in treating vitamin D deficiency or insufficiency.

6. Declarations

Funding: This study was entirely funded by Macleods Pharmaceuticals Ltd.

Conflict of interest: All authors are full-time employees of Macleods Pharmaceuticals Ltd.

Ethical approval: This study was approved by Ethics Committee.

Acknowledgements

The authors acknowledge the efforts of the statistician involved in analyzing the data.

References

- [1] World Health Organization. Vitamin D nutrition with a focus on the prevention of rickets and vitamin D deficiency in pregnant women, Apr 2015.
- [2] Sapkal N, Chhaya G, Satya M, Shah D, Clinical efficacy of different dosage forms containing vitamin D: design and study outcomes of a randomized, comparative clinical trial. *Int J Clin Trials*, vol. 7, no. 3, pp. 176-187, Aug. 2020.
- [3] Žmitek K, Hribar M, Hristov H, Pravst I, Efficiency of vitamin D supplementation in healthy adults is associated with body mass index and baseline serum 25-hydroxyvitamin D level, *Nutrients*, vol. 12, no. 5, pp. 1268, Apr. 2020.
- [4] Nandgaye KM, Samant RS, Kadam SB, Palkar PJ, Relative oral bioavailability of three formulations of vitamin D3: an open-label, three-treatment study, *Int J Basic Clin Pharmacol*, vol. 8, no. 1, pp. 138-142, Jan. 2019.
- [5] Koshy KT, Vitamin D: an update, *J Pharm Sci*, vol. 71, no. 2, pp. 137-153, Feb. 1982.
- [6] Nair R, Maseeh A, Vitamin D: The "sunshine" vitamin, *J Pharmacol Pharmacother*, vol. 3, no. 2, pp. 118-126, Apr-Jun. 2012.
- [7] Rajakumar K, Heras JDL, Chen TC, Lee SJ, Holick MF, Arslanian SA, Vitamin D status, adiposity, and lipids in black American and Caucasian children, *J Clin Endocrinol Metab*, vol. 96, no. 5, pp. 1560-1567, May. 2011.
- [8] Hensel KJ, Randis TM, Gelber SE, Ratner AJ, Pregnancy-specific association of vitamin D deficiency and bacterial vaginosis, *Am J Obstet Gynecol*, vol. 204, no. 1, pp. 41.e1-9, Jan. 2011.
- [9] Binkley N, Krueger D, Evaluation and correction of low vitamin D status, *Curr Osteoporos Rep*, vol. 6, no. 3, pp. 95-99, Sep. 2008.
- [10] U. S. Department of Health & Human Services. National Institutes of Health. Calcium fact sheet for consumers Updated Mar 22, 2021.
- [11] Kennel KA, Drake MT, Hurley DL, Vitamin D deficiency in adults: when to test and how to treat, *Mayo Clin Proc*, vol. 85, no. 8, pp. 752-7; quiz 757-758, Aug. 2010.
- [12] Meehan M, Penckofer S, The role of vitamin D in the aging adult, *J Aging Gerontol*, vol. 2, no. 2, pp. 60-71, Dec. 2014.
- [13] Plotnikoff GA, Weather or not: the importance of vitamin D status monitoring and supplementation, *Minn Med*, vol. 92, no. 11, pp. 43-46, Nov. 2009.
- [14] Chiang CM, Ismaeel A, Griffis RB, Weems S, Effects of vitamin D supplementation on muscle strength in athletes: a systematic review, *J Strength Cond Res*, vol. 31, no. 2, pp. 566-574, Feb. 2017.
- [15] Reid IR, Bolland MJ, Grey A, Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis, *Lancet*, vol. 383 (9912), pp. 146-155, Jan. 2014.
- [16] Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B, Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials, *JAMA*, vol. 293, no. 18, pp. 2257-2264, May. 2005.